Tes Pharma S.r.l.

This early-stage study tests the safety of a new drug, TESP-0401, in 68 healthy volunteers. Participants receive either the drug or a placebo as a single dose or daily for 7 days. Researchers will monitor side effects and measure how the body processes the drug.